Neuroendocrine Carcinoma of the Gastrointestinal Tract

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS research · 2026-01-13
Clinical Trial Update: Trial of FOLFIRI + Zimberelimab + Domvanalimab vs FOLFIRI With a Hybrid Synthetic Control Arm in Second Line Treatment of Neuroendocrine Carcinoma of Gastro-enteropancreatic or Unknown Origin (REWENEC 01) [Phase 2]
Phase 2 clinical trial assessing FOLFIRI plus zimberelimab and domvanalimab versus FOLFIRI with a synthetic control arm in second-line neuro…